NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more
NEWRON PHARMACEUT. EO-20 (NP5) - Total Assets
Latest total assets as of June 2025: €61.39 Million EUR
Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) holds total assets worth €61.39 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NEWRON PHARMACEUT. EO-20 - Total Assets Trend (2005–2024)
This chart illustrates how NEWRON PHARMACEUT. EO-20’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NEWRON PHARMACEUT. EO-20 - Asset Composition Analysis
Current Asset Composition (December 2024)
NEWRON PHARMACEUT. EO-20's total assets of €61.39 Million consist of 95.6% current assets and 4.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.9% |
| Accounts Receivable | €42.42 Million | 66.4% |
| Inventory | €7.92K | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how NEWRON PHARMACEUT. EO-20's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NEWRON PHARMACEUT. EO-20's current assets represent 95.6% of total assets in 2024, an increase from 90.6% in 2005.
- Cash Position: Cash and equivalents constituted 10.9% of total assets in 2024, down from 74.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 66.4% of total assets.
NEWRON PHARMACEUT. EO-20 Competitors by Total Assets
Key competitors of NEWRON PHARMACEUT. EO-20 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
NEWRON PHARMACEUT. EO-20 - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - NEWRON PHARMACEUT. EO-20 generates 0.80x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, NEWRON PHARMACEUT. EO-20 generates $ 24.79 in net profit.
NEWRON PHARMACEUT. EO-20 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.51 | 3.73 | 9.39 |
| Quick Ratio | 1.51 | 3.83 | 10.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €20.39 Million | € 14.70 Million | € 38.92 Million |
NEWRON PHARMACEUT. EO-20 - Advanced Valuation Insights
This section examines the relationship between NEWRON PHARMACEUT. EO-20's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 271.28 |
| Latest Market Cap to Assets Ratio | 5.18 |
| Asset Growth Rate (YoY) | 147.1% |
| Total Assets | €63.91 Million |
| Market Capitalization | $331.04 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values NEWRON PHARMACEUT. EO-20's assets at a significant premium ( 5.18x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: NEWRON PHARMACEUT. EO-20's assets grew by 147.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NEWRON PHARMACEUT. EO-20 (2005–2024)
The table below shows the annual total assets of NEWRON PHARMACEUT. EO-20 from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €63.91 Million | +147.07% |
| 2023-12-31 | €25.87 Million | -30.46% |
| 2022-12-31 | €37.20 Million | -26.33% |
| 2021-12-31 | €50.49 Million | -1.39% |
| 2020-12-31 | €51.20 Million | -15.08% |
| 2019-12-31 | €60.29 Million | +0.48% |
| 2018-12-31 | €60.00 Million | -17.84% |
| 2017-12-31 | €73.02 Million | +29.04% |
| 2016-12-31 | €56.59 Million | +27.51% |
| 2015-12-31 | €44.38 Million | +19.71% |
| 2014-12-31 | €37.07 Million | +17.26% |
| 2013-12-31 | €31.62 Million | -29.18% |
| 2012-12-31 | €44.65 Million | +229.11% |
| 2011-12-31 | €13.57 Million | -29.09% |
| 2010-12-31 | €19.13 Million | -54.10% |
| 2009-12-31 | €41.68 Million | -31.16% |
| 2008-12-31 | €60.54 Million | -13.97% |
| 2007-12-31 | €70.37 Million | -18.33% |
| 2006-12-31 | €86.16 Million | +266.67% |
| 2005-12-31 | €23.50 Million | -- |